Summary
Our chemoimmunotherapy study shows significantly longer remission and survival in acute myelocytic leukemia (AML) patients who have been immunized with neuraminidase-treated allogeneic myeloblasts as compared to patients who received chemotherapy alone or neuraminidase-treated myeloblasts plus MER. MER impairs the immunotherapeutic effectiveness of neuraminidase-treated allogeneic myeloblasts in AML patients. The in vivo and in vitro immunologic status in each arm of the protocol correlate well with the duration of remission and survival of the patient.
This work was supported in part by grant and contracts CA-1-5936-02, CA-5834, NCI Cancer Virus Program 1-CB-43879 and NCI Immunotherapy Program 1-CO-432225, and the T.J. Martell Memorial Fund for Leukemia Research. We express our appreciation to the Behring Institute,Behringwerk AG,Marburg, Federal Republic of Germany, for supplying the highly purified neuraminidase for this study. We also thank Patricia Mason, Svetlana Perova, and Khanitha Tangnavarad for the excellent assistance in performing the immunotherapeutic manipulation and Rogena Brown for secretarial assistance
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bagshawe KD, Currie GA (1968) Immunogenicity of L1210 murine leukemia cells after treatment with neuraminidase. Nature 218:1254
Bekesi JG, St Arneault G, Holland JF (1971) Increase of leukemia L1210 immunogenicity by Vibrio cholerae neuraminidase treatment. Cancer Res 31:2130
Bekesi JG, St Arneault G, Walter L, Holland JG (1972) Immunogenicity of leukemia L1210 cells after neuraminidase treatment. J Natl Cancer Inst 41:107
Bekesi JG, Roboz JP, Walter L, Holland JF (1974) Stimulation of specific immunity against cancer by neuraminidase-treated tumor cells. Behring Inst Mitt 55:309
Bekesi JG, Holland JF, Fleminger R, et al. (1977) Immunotherapeutic efficacy of neuraminidase-treated allogeneic myeloblasts in patients with acute myelocytic leukemia. In: Chirigos MA (ed) Control of neoplasia by modulation of the immune system. Raven Press, New York, p 573
Bekesi JG, Roboz JP, Holland JF (1976) Therapeutic effectiveness of neuraminidase-treated tumor cells as an immunogen in man and experimental animals with leukemia. Ann NY Acad Sci 277: 313
Bekesi JG, Holland JF (1979) Impact of specific immunotherapy in acute myelocytic leukemia. In: Neth R (ed) Modern trends in human leukemia III. Springer, Berlin Heidelberg New York, p 79
Currie GA, Bagshawe KD (1969) Tumor-specific immunogenicity of methylcholan- threne-induced sarcoma cells after incubation in neuraminidase. Br J Cancer 23:141
Gutterman JU, Rodriquez V, Mavligit G, Burgess MA, Geham E, Hersh EM, McCredie KB, Reed R, Smith T, Bodey GP, Freireich EJ (1974) Chemoimmunotherapy of adult acute leukemia: Prolongation of remission in myeloblasts leukemia with BCG. Lancet 2: 1405
Holland JF, Bekesi JG (1976) Immunotherapy of human leukemia with neuraminidase-modified cells. Med Clin North Am 60:539
Hughes RC, Sanford BH, Jeanloz RW (1972) Regeneration of the surface glycoproteins of a transplantable mouse tumor cells after treatment with neuraminidase. Proc Natl Acad Sci USA 69:942
Lee A (1968) Effect of neuraminidase on the phagocytosis of heterologous red cells by mouse peripheral macrophages. Proc Soc Exp Biol Med 128:891
Lindenmann J, Klein PA (1967) Immunological aspects of viral oncolysis. Recent Adv Cancer Res 9: 66
Mathe G (1972) Immunological approaches to the treatment of acute leukemia. Clin Haematol 1:165
Powles RL, Crowther D, Bateman CJ, Beard ME, McElwain TJ, Russell J (1973) Immunotherapy for acute myelogenous leukemia. 28:365
Sanford BH (1967) An alteration in tumor histocompatability induced by neuraminidase. Transplantation 5:1273
Schmidtke JR, Simmons RL (1975) Augmented uptake of neuraminidase-treated sheep red blood cells: Participation of opsome factors. J Natl Cancer Inst 54:1379
Sedlacek HH, Seiler FR (1978) Immunotherapy of neoplastic diseases with neuraminidase: Contradictions, new aspects, and revised concepts. Cancer Immunol Immunother 5:153
Sedlacek HH, Seiler FR, Schwick HG (1977) Neuraminidase and tumor immunotherapy. Klin Wochenschr 55:199
Sethi KK, Brandis H (1973) Neuraminidase-induced loss in the transplantability of murine leukemia L1210 induction of immunoprotection and the transfer of induced immunity to normal DBA/2 mice by serum and peritoneal cells. Br J Cancer 27:106
Sethi KK, Frandis H (1973) Synergistic cytotoxic effect of macrophages and normal mouse serum on neuraminidase-treated murine leukemia cells. Eur J Cancer 9:809
Sethi KK, Teschner M (1974) Neuraminidase-induced immunospecific destruction of transplantable experimental tumors. Postepy Hig Med Dosw 28:103
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Bekesi, J.G., Holland, J.F. (1982). Therapeutic Effectiveness of Neuraminidase-Treated Allogeneic Myeloblasts as Immunogen in Acute Myelocytic Leukemia. In: Mathé, G., Bonadonna, G., Salmon, S. (eds) Adjuvant Therapies of Cancer. Recent Results in Cancer Research, vol 80. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81685-7_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-81685-7_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81687-1
Online ISBN: 978-3-642-81685-7
eBook Packages: Springer Book Archive